Tanya M. Wildes - Concepedia

Author

Tanya M. Wildes

Washington University in St. Louis ORCID

Also Known As

Giri, Smith, Grant, Shakira J., Holstein, Sarah A., Kaufman, Jonathan L, Shah, Nina, Shain, Kenneth H., Silbermann, Rebecca, T M Wildes, T Wildes, T. M. Wildes

388

Publications

7.8K

Citations

H-Index

106

Concepts

All Affiliations

Washington University in St. Louis City of Hope The Ohio State University University of California, San Francisco University of North Carolina at Chapel Hill

About

Tanya M. Wildes is an author at Washington University in St. Louis specializing in medicine, oncology, and geriatrics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	26	55	2.6K
2	Health Sciences	13	16	706
3	Public Health	8	8	256
4	Nursing	6	6	293
5	Social Sciences	1	1	26

Tanya M. Wildes

100

Publications

5.5K

Citations

H-Index

Page 1

	Year	Citations
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial Peter M. Voorhees, Jonathan L. Kaufman, Jacob P. Laubach, Blood	2020	653
Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study Supriya G. Mohile, Mostafa Mohamed, Huiwen Xu, The Lancet Geriatric OncologyOncologyGeriatricsToxic EffectsCancer Management	2021	513
Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline Joseph Mıkhael, Nofisat Ismaila, Matthew C. Cheung, Journal of Clinical Oncology	2019	319
Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score Kristen M. Sanfilippo, Suhong Luo, Tzu‐Fei Wang, American Journal of Hematology	2019	168
Time to Stop Saying Geriatric Assessment Is Too Time Consuming Marije E. Hamaker, Tanya M. Wildes, Siri Rostoft Journal of Clinical Oncology	2017	155
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial Peter M. Voorhees, Douglas W. Sborov, Jacob P. Laubach, The Lancet Haematology Transplantation-eligible PatientsHematological MalignancyTransplantationHealth SciencesImmunotherapy	2023	139
Senior Adult Oncology, Version 2.2014 Arti Hurria, Tanya M. Wildes, Sarah L. Blair, Journal of the National Comprehensive Cancer Network Surgical OncologyAdvanced AgeAgingCancer ManagementGeriatric Medicine	2014	137
Development and Validation of a Risk Tool for Predicting Severe Toxicity in Older Adults Receiving Chemotherapy for Early-Stage Breast Cancer Allison Magnuson, Mina S. Sedrak, Cary P. Gross, Journal of Clinical Oncology	2021	136
NCCN Guidelines Insights: Older Adult Oncology, Version 2.2016 Noam VanderWalde, Reshma Jagsi, Efrat Dotan, Journal of the National Comprehensive Cancer Network Cancer ManagementNccn Guidelines InsightsSurgeryCancer EducationRadiation Medicine	2016	121
Geriatric assessment is associated with completion of chemotherapy, toxicity, and survival in older adults with cancer Tanya M. Wildes, Alexander P. Ruwe, C. Fournier, Journal of Geriatric Oncology Palliative CareGeriatric OncologyAgingGeriatricsLongevity	2013	120

Page 1